Hologic lowered its fiscal 2025 revenue forecast, citing weakness in sales of its breast health products, sending the company ...

Medical technology company Hologic (NASDAQ:HOLX) met Wall Street’s revenue expectations in Q4 CY2024, but sales were flat ...

Hologic (HOLX) delivered earnings and revenue surprises of 0.98% and 0%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

The company guided Q2 2025 revenues to be between $995 million and $1.005 billion, with non-GAAP EPS expected in the range of $1 to $1.03. Full-year revenue guidance was revised to $4.05 billion to $4 ...

Q1 2025 Earnings Conference Call February 5, 2025 4:30 PM ETCompany ParticipantsMike Watts - Corporate Vice President, ...

BTIG analyst Ryan Zimmerman maintained a Hold rating on Hologic (HOLX – Research Report) yesterday. The company’s shares closed yesterday at ...

While reporting its results for the first quarter, Hologic, Inc. (HOLX) revised its outlook for the full year 2025. Looking forward ...

Fintel reports that on February 3, 2025, Needham downgraded their outlook for Hologic (NasdaqGS:HOLX) from Buy to Hold.

Hologic (NASDAQ:HOLX – Get Free Report) will likely be issuing its quarterly earnings data after the market closes on ...

Hologic Inc (NASDAQ:HOLX). reported its financial results for the first quarter of fiscal year 2025, showing a slight beat in earnings per share (EPS) but falling short on revenue expectations. The ...

Learn more about whether Alcon Inc. or Hologic, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Shares of Hologic Inc. HOLX rallied 1.06% to $72.17 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.53% to 6,071.17 and ...